Neurocrine Bio. (NBIX) PT Raised to $131 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. LITE
8. NVT
9. BP
10. SPY

Go back to Neurocrine Bio. (NBIX) PT Raised to $131 at H.C. Wainwright

Neurocrine Bio. (NBIX) and TAK Collaboration Could Be Transformative - Canaccord Genuity

June 18, 2020 11:34 AM EDT

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $134.00 price target on Neurocrine Bio. (NASDAQ: NBIX), citing a major pact with Takeda Pharmaceutical Co Ltd. (NYSE: TAK) to develop seven neuropsychiatry-focused products. The deal helps bolster Neurocrine as a company not solely dependent on Ingrezza, as well as makes Neurocrine a key player in neuro-focused business development. These components all make NBIX more of a hunter than the... More